NEO-FRADIN Drug Patent Profile
Which patents cover Neo-fradin, and what generic alternatives are available?
Neo-fradin is a drug marketed by X Gen Pharms and is included in one NDA.
The generic ingredient in NEO-FRADIN is neomycin sulfate. There is one drug master file entry for this compound. Four suppliers are listed for this compound. Additional details are available on the neomycin sulfate profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Neo-fradin
A generic version of NEO-FRADIN was approved as neomycin sulfate by TEVA on December 31st, 1969.
AI Deep Research
Questions you can ask:
- What is the 5 year forecast for NEO-FRADIN?
- What are the global sales for NEO-FRADIN?
- What is Average Wholesale Price for NEO-FRADIN?
Summary for NEO-FRADIN
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 90 |
| Patent Applications: | 647 |
| DailyMed Link: | NEO-FRADIN at DailyMed |
US Patents and Regulatory Information for NEO-FRADIN
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| X Gen Pharms | NEO-FRADIN | neomycin sulfate | SOLUTION;ORAL | 065010-001 | May 23, 2002 | DISCN | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
